Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy.

Elodie Bousquet, Brian A Lee, Ahmad Santina, SriniVas Sadda, David Sarraf

Open access · goldAbstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 48% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Elodie BousquetRetinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.

Brian A LeeRetinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.

Ahmad SantinaRetinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.

SriniVas SaddaDoheny Eye Institute, Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, United States.

David SarrafRetinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute University of California Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.

University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To report the development of type 3 macular neovascularization (MNV) in a patient with pentosan polysulfate sodium (PPS) maculopathy one year after PPS cessation. Observation: A 72-year-old woman presented for decreased visual acuity in the left eye. Medical history was significant for interstitial cystitis treated with PPS for 11 years (cumulative dose of 1205 g) and PPS maculopathy. PPS was discontinued 1 year prior to presentation. Blue-light fundus autofluorescence and spectral domain optical coherence tomography confirmed the diagnosis of bilateral PPS maculopathy. OCT-angiography illustrated the development of type 3 MNV with intraretinal fluid in the left eye. Intravitreal injections of aflibercept were initiated with a good visual and anatomical response. Conclusion and importance: This report describes the development of type 3 MNV in a patient with PPS macular toxicity one year after PPS cessation. This complication emphasizes the need for regular retinal surveillance even after discontinuation of the inciting drug.

Indexed as

Anti-VEGFMultimodal imagingPentosan polysulfate sodium maculopathyType 3 macular neovascularization

Identifiers

PMID36561881

DOI10.1016/j.ajoc.2022.101771

PMCPMC9763375

OpenAlexW4310675542

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.